NKTR 358

Drug Profile

NKTR 358

Alternative Names: NKTR-358

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics
  • Class Immunotherapies
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 01 Mar 2018 Nektar Therapeutics plans a phase I/II multiple ascending dose trial in Systemic lupus erythematosus in the second quarter of 2018
  • 07 Nov 2017 Pharmacodynamics data from a preclinical trial in Autoimmune disorders released by Nektar Therapeutics
  • 24 Jul 2017 Nektar Therapeutics and Eli Lilly agree to co-develop NKTR 358 for Autoimmune disorders worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top